“Dr. Srinivasan is a senjor scientist werking for a reputed hiotechnology company known for its cutting-edge research in pharmaceuticals. Dr. Srinivasan is heading a research team, working on a new drug aimed at treating a rapidly spreading variant of a new viral infectious disease. The disease has been rapidly spreading across the world and the cases reported in the country are increasing. There is huge pressure on Dr. Srinivasan’s team to expedite the trials for the drug as there is significant market for it, and the company wants to get the first-mover advantage in the market. During a team meeting, some senior team members suggest some shortcut for expediting the clinical trials for the drug and for getting the requisite approvals. These include manipulating data to exclude some negative outcomes and selectively reporting positive results, foregoing the process of informed consent and using compounds already patented by a rival company, rather than developing one’s own component. Dr. Srinivasan is not comfortable taking such shortcuts, at the same time he realises meeting the targets is impossible without using these means. (a)What would you do in such a situation? (b)Examine your options and consequences in the light of the ethical questions involved. (c)How can data ethics and drug ethics save humanity at large in such a scenario?”
This question is available to read here. The practice button generates a fresh question from the same paper. Here, practise an answer plan in keywords. Choose your timer on the next screen. Feedback uses our common 15-point practice rubric, rather than the paper’s original mark allocation.
On September 29, 2026, the United States announced a zero-percent tariff regime for specific categories of speciality drugs imported from 20 nations, including India. This policy adjustment targets life-saving pharmaceutical segments, including gene therapies, cell therapies, antibody-drug conjugates, rare disease medications, and infertility treatments. By removing tariff barriers for these complex medical products, the U.S. aims to diversify its pharmaceutical supply chains and lower costs for advanced healthcare. For India, the 'pharmacy of the world', this decision creates a significant incentive to transition beyond traditional generic manufacturing toward high-value biopharmaceuticals and complex medicinal components.
At the seventy-second National Film Awards ceremony held at Ekta Nagar near the Statue of Unity, President Droupadi Murmu commended the Indian cinema industry for its expansive cultural reach while issuing a sharp caution against endorsing harmful health products. Emphasizing that a true star spreads light rather than darkness, the President highlighted the profound moral and social responsibilities borne by public figures whose commercial choices directly shape public health, impressionable youth, and societal values.
Union Home Minister Amit Shah announced at a national conference that India's illegal drug trade will be completely uprooted by the end of 2029. Highlighting a critical paradigm shift in national security enforcement, the address emphasized moving beyond peripheral street-level seizures to systematically dismantling entire trafficking syndicates. The strategy prioritizes rigorous financial investigations, tracing complex digital footprints, and aggressively targeting the accumulated profits generated by drug cartels. This renewed timeline underscores the growing threat posed by organized crime syndicates to India's demographic dividend and internal stability, necessitating a synchronized, technology-driven multi-agency response across federal and state jurisdictions.